HWN Suggests

Chondrosarcoma Patient Registry

Chondrosarcoma is a rare bone cancer that currently has no cure. Its prevalence and origin are unknown. Because chondrosarcoma is rare, there is also a lack of knowledge of the demographics of those who develop chondrosarcoma and only speculation on the cellular and genetic origins of the disease. The patient registry creates a platform for patients around the world to strengthen their voices and provide critical information about their experiences living with this rare bone cancer. This global resource will provide data for researchers to use to advance drug development and treatment options to help improve patient care. “Our goal is to enroll as many patients, or their parents or legal…

read full article

Articles of Interest

A Message to Chondrosarcoma Patients: Shayna’s Rare Cancer Story

Through sharing Shayna’s story, my goal is to give some direction to patients and families who have been newly diagnosed with chondrosarcoma. I want to stress the importance of advocating for patients’ treatment by insisting to cast a wide net and examine all available treatment options and verifying through second and third opinions that the treatment decisions made are the right ones.

Chondroma and chondrosarcoma

A chondrosarcoma is the most common primary malignant tumor of the chest wall. It usually presents on the anterior chest wall arising from the costochondral arches or sternum. It may occur as the result of malignant degeneration of a benign chondroma. Both chondrosarcomas and benign chondromas present as painful, slow-growing, hard, fixed, and nontender anterior chest wall masses.

Chondrosarcoma: A Clinical Review

Chondrosarcomas are a heterogenous group of cartilage forming neoplasms and represent the second most common primary bone malignancy. The diagnosis and grading of chondrosarcoma remain challenging, in particular on a biopsy specimen, and treatment decisions should be made by a multidisciplinary team. Surgical management remains the mainstay of treatment as chondrosarcoma is resistant to both radiation and chemotherapy. Novel targeted therapies have shown promise in preclinical studies but future trials are needed to determine their efficacy in the clinical setting. Survival rates vary significantly based on tumor grade and presence of metastases.

Chondrosarcoma: A Rare Misfortune in Aging Human Cartilage?

Unlike other malignant bone tumors including osteosarcomas and Ewing sarcomas with a peak incidence in adolescents and young adults, conventional and dedifferentiated chondrosarcomas mainly affect people in the 4th to 7th decade of life. To date, the cell type of chondrosarcoma origin is not clearly defined.

Chondrosarcoma: Challenges in diagnosis, grading and the importance of proper classification

Chondrosarcomas may exhibit a wide range of behavior. Generally, chondrosarcomas are slow growing and relatively indolent but a subset show aggressive behavior and are associated with distant metastasis and poor outcomes. Therefore, the role of the pathologist is critical in properly grading and the classification of chondrosarcomas as histologic grade and subtype greatly dictates treatment and predicts behavior and prognosis. The purpose of this lesson is to review the challenges in the diagnosis of chondrosarcoma from the perspective of a pathologist with a special attention on chondrosarcoma variants.

Melinda’s chondrosarcoma journey

My life is changed by a single word - The next day I was diagnosed as 1 in 1,400 in the United States to have chondrosarcoma cancer. I was told I was in Stage 3. The mass had deteriorated much of the left pelvis bone. I had never heard the word chondrosarcoma, couldn’t pronounce or spell it. Yet this word will remain with me for the rest of my life.

The Clinical Approach Towards Chondrosarcoma

Chondrosarcomas constitute a heterogeneous group of neoplasms that have the production of cartilage matrix by the tumor cells in common. Chondrosarcoma is the third most common primary malignancy of bone after myeloma and osteosarcoma.

Resources

Chondrosarcoma Foundation

CS Foundation is committed to supporting the patients, families, and caregivers impacted by Chondrosarcoma, a rare and life-threatening form of bone cancer. We strive to improve public information regarding this disease as we build a robust network of resources for patients and physicians alike.

National Cancer Institute

The most common type of chondrosarcoma, called conventional chondrosarcoma, usually grows very slowly. Rare subtypes of chondrosarcoma, called dedifferentiated chondrosarcoma, myxoid chondrosarcoma, clear cell chondrosarcoma, and mesenchymal chondrosarcoma, may grow more quickly and may spread to other parts of the body.

Physiopedia

Chondrosarcomas are malignant cartilaginous tumours, accounting for ~25% of all primary malignant bone tumours. They are most commonly found in older patients, most commonly effecting the pelvis, sternum, scapula, or cartilage of long bones in the extremities.

Radiopaedia

Chondrosarcomas account for 20-25% of all bone tumors and are the third most common malignant bone tumor after myeloma and osteosarcoma. In patients aged >75 years, chondrosarcomas are the most common primary bone tumor.

SarcomaUK

It mostly affects adults above the age of 40 and the most common sites are the upper arm, pelvis and thigh bone. Chondrosarcomas make up 37% of all bone sarcoma diagnoses.

StatPearls

Chondrosarcomas are malignant cartilaginous neoplasms with diverse morphological features and clinical behavior. They account for about 20 percent of all primary malignant tumors of the bone and usually arise in the pelvis or long bones.